Loading...
BVMF
FLRY3
Market cap1.45bUSD
Dec 05, Last price  
14.49BRL
1D
-5.85%
1Q
-8.12%
Jan 2017
-17.81%
IPO
-4.92%
Name

Fleury SA

Chart & Performance

D1W1MN
BVMF:FLRY3 chart
P/E
12.82
P/S
1.03
EPS
1.13
Div Yield, %
3.35%
Shrs. gr., 5y
9.90%
Rev. gr., 5y
21.48%
Revenues
7.68b
+18.76%
487,588,000551,230,000675,280,000770,109,000871,541,0001,125,741,0001,501,783,0001,656,896,0001,678,900,0001,894,960,0002,096,113,0002,383,012,0002,664,463,0002,905,107,0002,971,616,0003,872,651,0004,463,040,0006,470,850,0007,684,659,000
Net income
616m
+45.41%
32,112,00025,315,00041,962,00083,685,000130,001,000100,647,000106,588,00061,143,00085,802,000107,343,000228,749,000320,618,000331,585,000312,317,000256,961,000349,926,000307,908,000423,758,000616,172,000
CFO
1.93b
+34.13%
71,329,00079,480,00072,398,00024,031,000112,919,000145,960,000167,054,000209,585,000285,709,000368,922,000513,870,000529,607,000701,485,000732,317,000647,141,0001,018,669,000987,133,0001,439,304,0001,930,488,000
Dividend
Aug 15, 20240.33738 BRL/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.
IPO date
Dec 16, 2009
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT